|
515 Companies |
|
302 Products |
|
302 Products |
|
167 Mechanisms of Action |
|
1404 Trials |
|
125634 News |
|
| «12...15391540154115421543154415451546154715481549...15771578» |
- dovitinib (TKI258) / Novartis, Oncoheroes, sunitinib / Generic mfg.
Trial initiation date, Combination therapy, IO biomarker, Stroma, Metastases: Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors (clinicaltrials.gov) - Jan 13, 2015
P1, N=33, Not yet recruiting, Sponsor: Asan Medical Center
Initiation date: Nov 2014 --> Mar 2015
- Avastin (bevacizumab) / Roche, carotuximab IV (ENV-105) / Kairos Pharma
Enrollment change, Trial primary completion date: Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - Jan 13, 2015
P2, N=128, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Nov 2014 --> Mar 2015 N=14 --> 128 | Trial primary completion date: Dec 2014 --> Dec 2016
- alisertib (MLN8237) / Puma
Enrollment change: Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus (clinicaltrials.gov) - Jan 13, 2015
P2, N=23, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=14 --> 128 | Trial primary completion date: Dec 2014 --> Dec 2016 N=50 --> 23
- ||||| famitinib (SHR 1020) / Jiangsu Hengrui Pharma
New P2 trial, Stroma: A Study of Famitinib in Patients With Gastrointestinal Stromal Tumor (clinicaltrials.gov) - Jan 13, 2015
P2, N=82, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- dimethyl fumarate / Generic mfg., temozolomide / Generic mfg.
New P1 trial: Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - Jan 13, 2015
P1, N=23, Not yet recruiting, Sponsor: Virginia Commonwealth University
- picropodophyllin (AXL1717) / Axelar
Trial primary completion date: Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas (clinicaltrials.gov) - Jan 12, 2015
P1/2, N=30, Recruiting, Sponsor: Rush University Medical Center
N=50 --> 23 Trial primary completion date: Dec 2013 --> Dec 2015
- cisplatin / Generic mfg., acetylcysteine solution / Generic mfg.
Trial initiation date, Trial primary completion date: NAC to Prevent Cisplatin-induced Hearing Loss (clinicaltrials.gov) - Jan 12, 2015
P1, N=24, Not yet recruiting, Sponsor: Children's Hospital Los Angeles
Trial primary completion date: Dec 2013 --> Dec 2015 Initiation date: Jul 2014 --> Jul 2015 | Trial primary completion date: Jul 2017 --> Jul 2018
- Trial primary completion date: Evaluating Bacterial Response in Sarcoma Management Using Fluorescence Imaging (clinicaltrials.gov) - Jan 9, 2015
P=N/A, N=20, Enrolling by invitation, Sponsor: University Health Network, Toronto
Initiation date: Jul 2014 --> Jul 2015 | Trial primary completion date: Jul 2017 --> Jul 2018 Trial primary completion date: Dec 2014 --> May 2015
- Caprelsa (vandetanib) / Sanofi
Trial primary completion date, Combination therapy: A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas (clinicaltrials.gov) - Jan 9, 2015
P2, N=112, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2014 --> May 2015 Trial primary completion date: Jul 2016 --> Jan 2016
- irinotecan / Generic mfg.
Combination therapy: Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas (clinicaltrials.gov) - Jan 9, 2015
P1, N=53, Not yet recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Jul 2016 --> Jan 2016 Initiation date: Dec 2014 --> Jul 2015 | Trial primary completion date: Dec 2017 --> Jul 2018
- Trial initiation date, Trial primary completion date: Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer (clinicaltrials.gov) - Jan 9, 2015
P=N/A, N=30, Not yet recruiting, Sponsor: University of Wisconsin, Madison
Initiation date: Dec 2014 --> Jul 2015 | Trial primary completion date: Dec 2017 --> Jul 2018 Initiation date: Mar 2014 --> Feb 2015 | Trial primary completion date: May 2014 --> Jun 2015
- topotecan / Generic mfg., melphalan / Generic mfg., busulfan / Generic mfg.
Enrollment change, Trial withdrawal: Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma (clinicaltrials.gov) - Jan 9, 2015
P=N/A, N=0, Withdrawn, Sponsor: City of Hope Medical Center
Initiation date: Mar 2014 --> Feb 2015 | Trial primary completion date: May 2014 --> Jun 2015 N=15 --> 0 | Recruiting --> Withdrawn
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Enrollment change: Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy (clinicaltrials.gov) - Jan 8, 2015
P2, N=26, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=15 --> 0 | Recruiting --> Withdrawn N=51 --> 26
- |||| selurampanel (BGG492) / Novartis
Enrollment open, Trial primary completion date: Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 (clinicaltrials.gov) - Jan 8, 2015
P2, N=77, Recruiting, Sponsor: Novartis Pharmaceuticals
N=51 --> 26 Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2014 --> Jun 2015
- || Votrient (pazopanib) / Novartis
Trial primary completion date, Combination therapy: Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma (clinicaltrials.gov) - Jan 7, 2015
P2, N=80, Recruiting, Sponsor: OHSU Knight Cancer Institute
Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2014 --> Jun 2015 Trial primary completion date: Mar 2015 --> Mar 2016
- || buparlisib (AN2025) / Novartis, Adlai Nortye
Trial primary completion date, Combination therapy, Stroma: A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients (clinicaltrials.gov) - Jan 7, 2015
P1, N=60, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Mar 2015 --> Mar 2016 Trial primary completion date: Dec 2014 --> Apr 2015
- || Piqray (alpelisib) / Novartis
Enrollment closed, Combination therapy, Stroma: A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients (clinicaltrials.gov) - Jan 7, 2015
P1, N=55, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2014 --> Apr 2015 Recruiting --> Active, not recruiting
- Trial completion: A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas (clinicaltrials.gov) - Jan 7, 2015
P1, N=34, Completed, Sponsor: University of California, San Francisco
Recruiting --> Active, not recruiting Recruiting --> Completed
- Avastin (bevacizumab) / Roche, carotuximab IV (ENV-105) / Kairos Pharma
Enrollment change: Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - Jan 6, 2015
P2, N=14, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed N=128 --> 14
- dasatinib / Generic mfg.
Enrollment change: Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma (clinicaltrials.gov) - Jan 6, 2015
P2, N=64, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=128 --> 14 N=113 --> 64
- Circulating tumor DNA, Stroma: GIST: Assessment of Tumor Mutations and TKI Plasma Exposure (clinicaltrials.gov) - Jan 6, 2015
P=N/A, N=300, Recruiting, Sponsor: University Medical Centre Groningen
- | Keytruda (pembrolizumab) / Merck (MSD)
New P1/2 trial, Metastases: Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) (clinicaltrials.gov) - Jan 6, 2015
P1/2, N=90, Recruiting, Sponsor: Western Regional Medical Center
- ganitumab (AMG 479) / Takeda, ImmunityBio
Metastases: AEWS1221: Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (clinicaltrials.gov) - Jan 2, 2015
P2, N=140, Recruiting, Sponsor: National Cancer Institute (NCI)
N=113 --> 64 Trial primary completion date: Dec 2015 --> Dec 2018
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Neulasta (pegfilgrastim) / Roche
Trial primary completion date: Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus (clinicaltrials.gov) - Jan 2, 2015
P2, N=51, Completed, Sponsor: Gynecologic Oncology Group
Trial primary completion date: Dec 2015 --> Dec 2018 Trial primary completion date: Feb 2007 --> Jan 2009
- Cometriq (cabozantinib capsule) / Exelixis, Ipsen, Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Enrollment change, Metastases: Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer (clinicaltrials.gov) - Jan 2, 2015
P2, N=72, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Feb 2007 --> Jan 2009 N=36 --> 72
- ganitumab (AMG 479) / Takeda, ImmunityBio
Metastases: AEWS1221: Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (clinicaltrials.gov) - Jan 2, 2015
P2, N=140, Recruiting, Sponsor: National Cancer Institute (NCI)
N=36 --> 72 Not yet recruiting --> Recruiting
- Cometriq (cabozantinib capsule) / Exelixis, Ipsen, Cabometyx (cabozantinib tablet) / Exelixis
Enrollment open: Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma (clinicaltrials.gov) - Jan 2, 2015
P2, N=85, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Enrollment closed, Metastases: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (clinicaltrials.gov) - Jan 2, 2015
P2, N=299, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Beleodaq (belinostat) / Aurobindo, Assertio
Enrollment change, Surgery: PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery (clinicaltrials.gov) - Dec 29, 2014
P2, N=13, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=37 --> 13
- docetaxel / Generic mfg., gemcitabine / Generic mfg.
Enrollment change: Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer (clinicaltrials.gov) - Dec 29, 2014
P2, N=28, Completed, Sponsor: Gynecologic Oncology Group
N=37 --> 13 N=60 --> 28
- | Lartruvo (olaratumab) / Eli Lilly
New P1 trial, Metastases: A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Dec 29, 2014
P1, N=24, Not yet recruiting, Sponsor: Eli Lilly and Company
- | mocetinostat (MGCD0103) / Otsuka, BMS
Trial initiation date, Metastases: SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma (clinicaltrials.gov) - Dec 27, 2014
P2, N=40, Not yet recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
N=60 --> 28 Initiation date: Dec 2014 --> Mar 2015
- | docetaxel / Generic mfg., gemcitabine / Generic mfg.
Trial completion: Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer (clinicaltrials.gov) - Dec 27, 2014
P2, N=28, Completed, Sponsor: Gynecologic Oncology Group
Initiation date: Dec 2014 --> Mar 2015 Active, not recruiting --> Completed
- methotrexate IV / Generic mfg.
Trial primary completion date, HEOR, Cost effectiveness: Outpatient Administration of High Dose Methotrexate (HD MTX) in Patients With Osteosarcoma (clinicaltrials.gov) - Dec 25, 2014
P3, N=12, Recruiting, Sponsor: The Hospital for Sick Children
Active, not recruiting --> Completed Trial primary completion date: Aug 2014 --> Aug 2015
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Mozobil (plerixafor) / Sanofi
Enrollment open: NCI-2013-00701: O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas (clinicaltrials.gov) - Dec 24, 2014
P1/2, N=24, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Aug 2014 --> Aug 2015 Suspended --> Recruiting
- gemcitabine / Generic mfg.
Trial primary completion date: PP-Gemcitabine & External Beam Radiation-Sarcomas (clinicaltrials.gov) - Dec 24, 2014
P1, N=36, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Suspended --> Recruiting Trial primary completion date: Dec 2014 --> Mar 2015
- Trial primary completion date, Metastases: Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors (clinicaltrials.gov) - Dec 24, 2014
P1/2, N=143, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Dec 2014 --> Mar 2015 Trial primary completion date: Feb 2015 --> Feb 2016
- Zolinza (vorinostat) / Merck (MSD)
Trial termination, Trial primary completion date: High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma (clinicaltrials.gov) - Dec 24, 2014
P1, N=30, Terminated, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Feb 2015 --> Feb 2016 Active, not recruiting --> Terminated | Trial primary completion date: Jul 2016 --> Aug 2013
- | imatinib / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date, Stroma, Metastases: SWOG-S0033: Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor (clinicaltrials.gov) - Dec 24, 2014
P3, N=748, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated | Trial primary completion date: Jul 2016 --> Aug 2013 N=600 --> 748 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2026 --> May 2007
- Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - Dec 24, 2014
P1, N=19, Completed, Sponsor: National Cancer Institute (NCI)
N=600 --> 748 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2026 --> May 2007 Active, not recruiting --> Completed
- Recentin (cediranib) / AstraZeneca, RG4733 / Roche
Trial completion, Enrollment change, Metastases: Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Dec 24, 2014
P1, N=20, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=50 --> 20
- ||| emactuzumab (RG7155) / SynOx Therap, Tecentriq (atezolizumab) / Roche
New P1 trial, Metastases: A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Dec 23, 2014
P1, N=110, Recruiting, Sponsor: Hoffmann-La Roche
- Halaven (eribulin mesylate) / Eisai
Trial suspension: AOST1322: Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma (clinicaltrials.gov) - Dec 19, 2014
P2, N=33, Suspended, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=50 --> 20 Recruiting --> Suspended
- | mebendazole / Generic mfg.
Enrollment change, Trial initiation date, Trial primary completion date: A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas (clinicaltrials.gov) - Dec 19, 2014
P1/2, N=36, Not yet recruiting, Sponsor: Mark Atlas
Recruiting --> Suspended N=20 --> 36 | Initiation date: Jun 2013 --> Jan 2015 | Trial primary completion date: Jun 2016 --> Jan 2018
- Votrient (pazopanib) / Novartis, BeiGene
Enrollment change, Trial termination, Combination therapy: Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) (clinicaltrials.gov) - Dec 19, 2014
P1/2, N=5, Terminated, Sponsor: Memorial Sloan-Kettering Cancer Center
N=20 --> 36 | Initiation date: Jun 2013 --> Jan 2015 | Trial primary completion date: Jun 2016 --> Jan 2018 N=61 --> 5 | Active, not recruiting --> Terminated; Lack of accrual
- ||| dasatinib / Generic mfg.
Enrollment change, Trial primary completion date, Metastases: Trial of Dasatinib in Advanced Sarcomas (clinicaltrials.gov) - Dec 19, 2014
P2, N=386, Active, not recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
N=61 --> 5 | Active, not recruiting --> Terminated; Lack of accrual N=502 --> 386 | Trial primary completion date: Dec 2014 --> Jun 2015
- New P1 trial, Metastases: NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy (clinicaltrials.gov) - Dec 19, 2014
P1, N=12, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
- |||||| veliparib (ABT-888) / AbbVie
Combination therapy, PARP Biomarker: A071102: Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - Dec 19, 2014
P2/3, N=440, Recruiting, Sponsor: National Cancer Institute (NCI)
N=502 --> 386 | Trial primary completion date: Dec 2014 --> Jun 2015 Not yet recruiting --> Recruiting
- |||| Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Trial primary completion date, Metastases: Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors (clinicaltrials.gov) - Dec 19, 2014
P2, N=74, Completed, Sponsor: Sarcoma Alliance for Research through Collaboration
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Feb 2014 --> Jun 2014
- cyclophosphamide / Generic mfg.
Trial primary completion date, Metastases: Clinical Study of Metronomic Oral Cyclophosphamide in Patients With Advanced Sarcomas (clinicaltrials.gov) - Dec 17, 2014
P2, N=28, Recruiting, Sponsor: National Cancer Centre, Singapore
Active, not recruiting --> Completed | Trial primary completion date: Feb 2014 --> Jun 2014 Trial primary completion date: Aug 2014 --> Aug 2016